Roivant SciencesROIV
Market Cap: $9.1B
About: Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Employees: 908
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
124% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 29
23% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 82
14% more funds holding
Funds holding: 254 [Q1] → 290 (+36) [Q2]
3.85% more ownership
Funds ownership: 69.78% [Q1] → 73.63% (+3.85%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 19 [Q1] → 19 (+0) [Q2]
3% less capital invested
Capital invested by funds: $5.93B [Q1] → $5.75B (-$178M) [Q2]
14% less call options, than puts
Call options by funds: $10.5M | Put options by funds: $12.2M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Douglas Tsao 50% 1-year accuracy 70 / 139 met price target | 46%upside $18 | Buy Reiterated | 19 Aug 2024 |
Piper Sandler Allison Bratzel 70% 1-year accuracy 7 / 10 met price target | 79%upside $22 | Overweight Maintained | 10 Jul 2024 |
Financial journalist opinion
Based on 3 articles about ROIV published over the past 30 days